On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.

On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.